For transplant patients, the journey doesn’t end with a successful surgery. One of the critical aspects of post-transplant care is the use of types of drugs called “immunosuppressants”. These medications play a critical role in stopping the body’s immune system from rejecting the new organ. Understanding the types, functions, and importance of these medications, as well as the challenges in managing them, is very important for transplant recipients.
Types of Transplant Medications and Their Functions
Immunosuppressants can be broadly classified into several categories, each playing a unique role in ensuring the transplanted organ is not rejected:
- Calcineurin Inhibitors (CNIs): These include drugs like cyclosporine and tacrolimus. CNIs inhibit (i.e., slow down or stop) the activity of calcineurin, a protein that activates T-cells of the immune system thereby preventing rejection.
- Antiproliferative Agents: Medications such as mycophenolate mofetil (MMF) and azathioprine fall into this category. They work by inhibiting the growth of immune cells, further reducing the risk of rejection.
- mTOR Inhibitors: Drugs like sirolimus and everolimus inhibit the mammalian target of rapamycin (mTOR), a key protein involved in cell growth and proliferation, thus helping control the immune response.
- Steroids: Prednisone is a common steroid used to reduce inflammation and suppress (lower the activity of) the immune system. While highly effective, long-term use can lead to significant side effects.
NOTE: these are complicated terms and it may be hard to understand. Keep reading and refer back to the four types of drugs as needed.
Importance of Adherence to Medication Regimens
Adherence, which means consistently taking your medicine as instructed by your doctor, is crucial for transplant patients. Missing a dose of medication or not taking your medication at the correct time can lead to not having enough of the drugs that calm the immune system, which would increase the risk of organ rejection. Conversely, taking too much can be harmful as well. Therefore, it is very important for patients to follow their medication schedule with great care, go to their doctor and laboratory appointments, and share any issues with their healthcare team.
Challenges in Transplant Medication Management
Managing transplant medications can be hard due to many factors, including side effects, complications, and the complexity of the medication regimen.
Side Effects and Complications
Immunosuppressants, while lifesaving, come with a range of side effects. Common issues include:
- Infections: Suppressing the immune system increases the risk of infections.
- Kidney Damage: Particularly with CNIs, these drugs can hurt your kidney over time due to scarring.
- High Blood Pressure and Diabetes: These are common side effects of steroids and CNIs.
- Gastrointestinal Issues: Such as nausea, vomiting, and diarrhea, often seen with antiproliferative agents.
- Neurotoxicity: Tremors (or shaking), the most common finding, but also difficulty sleeping, brain fog, headache, dizziness, impaired sense of touch, light sensitivity and mood disturbance
- Cancer: Skin cancers, lymphomas, and other malignancies, as the immune system’s ability to detect and destroy cancerous cells is diminished.
Strategies for Managing Side Effects
Effective strategies to manage side effects include:
- Regular Monitoring: Transplant recipients need to get frequent blood tests to measure the levels of drugs in their system (and make sure there is not too much or too little of any drug) and to test how well the kidney is functioning.
- Lifestyle Adjustments: Transplant recipients can change their diet and add or modify their exercise routine to help manage or avoid high blood pressure and diabetes.
- Preventative Medications: Sometimes doctors will prescribe antibiotics (that fight infections) or antivirals (that fight viruses) to prevent infections (especially during the first few months after the transplant).
Addressing Non-Adherence and Its Implications
Non-adherence (not taking drugs as prescribed by your doctor) to immunosuppressant therapy can lead to severe consequences, including acute organ rejection and failure of the new transplant. Why would someone not take their medicines? Well, it is a pretty complex combination of drugs that need to be taken consistently, there is the possibility of side effects that might not be pleasant, and perhaps some people do not understand how important these medications are.
Some tips to keep on the program as prescribed by your doctor:
- Educate: Learn as much as you can about your drugs and how important they are. Also learn from other transplant recipients how they are managing to follow their routines successfully. Check out more articles on TransplantLyfe to help stay informed and meet people who are on the same journey.
- Simplify: Ask your doctor if there are any combination pills or options to reducing the number of daily doses to make it easier for patients to stick to your schedule. Perhaps try a pill box to sort drugs into morning and evening groups. And you can plan your drugs for the week ahead. You can also use an alarm clock or your phone to set reminders.
- Support: Ask family members, care partners, or support groups to help out. Reminders to do what you are meant to do, as well as a good bit of emotional support, are helpful.
Conclusion
Immunosuppressant medicines are a very critical part of post-transplant care as they are essential for preventing organ rejection. Understanding the different types of medications, their functions, and the importance of taking them correctly are crucial for transplant patients. While challenges exist, there are ways to help manage these issues, ensuring the long-term success of the transplant. Always consult with healthcare providers to ask questions and learn how to match the professionals’ recommendations with your individual needs and circumstances.
This article is made possible by the support of ITB-MED LLC.
Glossary
Acute Rejection: A type of rejection that occurs within days to months after a transplant. It is common but usually treatable if caught early.
Biopsy: A medical test involving the removal of a small piece of tissue to examine it for signs of disease or rejection.
Chronic Rejection: A type of rejection that happens over a long time, causing gradual damage to the transplanted organ.
Gene Editing (CRISPR): A technique used in research to alter genes to help the immune system accept transplanted organs.
Human Leukocyte Antigens (HLAs): Proteins on the surface of cells that are unique to each person and help the immune system recognize which cells belong in the body and which do not.
Hyperacute Rejection: A type of rejection that happens very quickly, within minutes to hours after a transplant, due to immediate blood clotting in the transplanted organ.
Immune System: A complex network of cells, chemicals, tissues, and organs that work together to defend the body against harmful invaders.
Immunology: The study of the immune system, which protects the body from harmful things like viruses, bacteria, and even transplanted organs.
Immunosuppressive Drugs: Medications that reduce the activity of the immune system to prevent it from attacking the transplanted organ.
Long-Term Immunosuppression: Ongoing treatment with immunosuppressive drugs to prevent rejection of a transplanted organ.
Monitoring: Regular check-ups and tests with healthcare providers to detect and treat any signs of rejection early.
Rejection: When the immune system attacks a transplanted organ or tissue, thinking it is harmful.
Tolerance: A state in which the immune system accepts the transplanted organ as part of the body and does not attack it, reducing the need for long-term immunosuppressive drugs.
What are Endpoints? How can endpoints make clinical trials more patient-friendly and lead to better drugs?
Introduction
Clinical trials are essential for discovering new treatments and medical procedures. A critical part of these trials is choosing and evaluating endpoints, which are the key results used to measure a trial’s success. This article explains the goals and different types of endpoints in clinical trials, the importance of patient-reported outcomes, and how to design better trials, especially for transplant patients.
Understanding Objectives and Endpoints
The main goal of a clinical trial is to see how well and safely a treatment works. Endpoints are the specific results or events used to measure the trial’s success. For example, in cancer trials, an endpoint might be a reduction in tumor size. In transplantation trials, it could be how well the new organ is working. Other general health indicators include survival rates and the severity of side effects.
Different Types of Endpoints
There are several types of endpoints in clinical trials:
- Primary Endpoints: The main results used to determine if the treatment is successful.
- Secondary Endpoints: Additional results that provide more information about the treatment’s effects or side effects.
- Exploratory Endpoints: Used to explore other potential outcomes and generate ideas for future research.
- Surrogate Endpoints: Substitute markers that are believed to indirectly reflect longer-term patient outcomes.
Surrogate endpoints are used when the primary endpoints take too long to measure. For example, lowering blood cholesterol might be used as a surrogate endpoint for preventing heart attacks.
Outcomes
Clinical outcomes (results) come from many sources. There are data collected from objective measures like an X-ray or a blood test. Patient-reported outcomes (PROs) are one type of clinical outcome assessment becoming more important in clinical trials.
Others include clinician-reported outcomes (ClinROs), which are health assessments made by doctors, observer-reported outcomes (ObsROs), which are evaluations by care partners, and performance outcomes (PerfOs), which are measures of a patient’s ability to do certain tasks.
PROs are results based on what patients say about their own health, symptoms, and quality of life. Including PROs in trials helps make research more focused on the patient, enabling healthcare providers to understand the experimental drug’s benefits and side effects from their perspective.
Using PROs can greatly improve drug development by:
- Providing direct insights into the patient’s experience, leading to more patient-centered drug development.
- Identifying benefits or side effects that might not be seen through traditional measurements.
- Providing additional data that can aid in the approval process by showing clear benefits from the patient’s viewpoint.
Future Clinical Trials Design for Improved Outcomes After Transplantation
Designing better clinical trials for transplantation should focus on improving long-term patient and organ survival. This involves:
Enhancing Endpoint Selection: Using a mix of traditional and new endpoints, including molecular and genetic markers, which allow for more precise tailoring of the response, to predict organ function and survival, as well as patient response and changes.
- Incorporating Comprehensive PROs: Including endpoints that reflect the patient’s quality of life after transplantation, which is very important in evaluating the success of the procedure.
- Utilizing Adaptive Trial Designs: These allow changes based on early results, potentially reducing costs and time, and improving the relevance and ethical aspects of the trials.
Conclusion
Rethinking endpoints in clinical trials is vital for advancing medical research and improving patient care. By including patient-reported outcomes and refining endpoint selection, especially in transplantation, researchers can achieve more meaningful and impactful results. Moving forward, clinical trial designs should better match the complexities of human health, ensuring new treatments and procedures are both effective and patient centered.
This article is made possible by the support of ITB-MED LLC.
Glossary
Endpoints: The key results used to measure a trial’s success
Genetic Markers: Pieces of DNA that can provide information about a person’s risk for certain diseases or how they might respond to a treatment.
Molecular Markers: Tiny parts of cells, like proteins or DNA, that can give clues about how an organ is working or how a disease is progressing.
Dr. Newell graduated from Kalamazoo College and the University of Michigan Medical School. Following a residency in general surgery at Loyola University Medical Center, he obtained a PhD in immunology and completed a fellowship in transplantation surgery at the University of Chicago. After seven years as a faculty member at the University of Chicago, he moved to Emory University, where he is Professor of Surgery and Vice Chair for Academic Affairs.
Dr. Newell’s clinical practice focuses on kidney transplantation in adults and children, pancreas transplantation, and living kidney donation. His research interests span the spectrum from basic laboratory investigation to clinical trials focusing on alloimmunity, immunosuppression, and tolerance. He has lead numerous studies supported by the NIH and the Immune Tolerance Network.
Dr. Newell has served the transplant community in a variety of roles. He is a Past President of the American Society of Transplantation. He has served the NIH sponsored Clinical Trials in Organ Transplantation (CTOT) consortium in many different roles. He is an associate editor for the American Journal of Transplantation and previously served as a member of the NIH study section Transplantation, Tolerance, and Tumor Immunology. He currently serves as an AST representative on the Transplant Therapeutics Consortium and is the co-chair of Workgroup 1, which is focused on gaining regulatory endorsement of new surrogate endpoints for clinical trials.
Anne B. Lawler, CSW, LCSW, ACSW, BCD, is a licensed clinical social worker in New York State. She has extensive experience in social work with transplantation support groups and mentoring programs.